Evidence map›Paper›PMID 35689194›Full record

ArticleBMC cancer2022

YAP1 is essential for malignant mesothelioma tumor maintenance.

Loreley Calvet, Odette Dos-Santos, Emmanuel Spanakis, Véronique Jean-Baptiste, Jean-Christophe Le Bail, Armelle Buzy, Pascal Paul, Christophe Henry, Sandrine Valence, Colette Dib and 5 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Targeting TEAD in cancer.Frontiers in oncology · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. TEAD Inhibitors Sensitize KRASPharmaceuticals (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Loreley CalvetDepartment of Oncology, In Vivo Pharmacology, Sanofi Research Center, Vitry-sur-Seine, France. loreley.calvet@sanofi.com.
Odette Dos-SantosDepartment of Oncology, Molecular Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
Emmanuel SpanakisDepartment of Oncology, Precision Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
Véronique Jean-BaptisteDepartment of Oncology, Molecular Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
Jean-Christophe Le BailDepartment of Oncology, Molecular Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
Armelle BuzyDepartment of Translational Sciences, Sanofi Research Center, Chilly Mazarin, France.
Pascal PaulDepartment of Translational Sciences, Sanofi Research Center, Chilly Mazarin, France.
Christophe HenryDepartment of Oncology, Molecular Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
Sandrine ValenceDepartment of Oncology, Precision Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
Colette DibDepartment of Oncology, Precision Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
Jack PollardDepartment of Oncology, Precision Oncology, Sanofi Research Center, Cambridge, USA.
Sukhvinder SidhuDepartment of Oncology, In Vivo Pharmacology, Sanofi Research Center, Vitry-sur-Seine, France.
Jürgen MollDepartment of Oncology, Molecular Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
Laurent DebusscheDepartment of Oncology, In Vivo Pharmacology, Sanofi Research Center, Vitry-sur-Seine, France.
Iris ValtingojerDepartment of Oncology, Molecular Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
Sanofi (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant pleural mesothelioma, a tumor arising from the membrane covering the lungs and the inner side of the ribs, is a cancer in which genetic alterations of genes encoding proteins that act on or are part of the Hippo-YAP1 signaling pathway are frequent. Dysfunctional Hippo signaling may result in aberrant activation of the transcriptional coactivator protein YAP1, which binds to and activates transcription factors of the TEAD family. Recent studies have associated elevated YAP1 protein activity with a poor prognosis of malignant mesothelioma and its resistance to current therapies, but its role in tumor maintenance is unclear. In this study, we investigate the dependence of malignant mesothelioma on YAP1 signaling to maintain fully established tumors in vivo. We show that downregulation of YAP1 in a dysfunctional Hippo genetic background results in the inhibition of YAP1/TEAD-dependent gene expression, the induction of apoptosis, and the inhibition of tumor cell growth in vitro. The conditional downregulation of YAP1 in established tumor xenografts leads to the inhibition of YAP1-dependent gene transcription and eventually tumor regression. This effect is only seen in the YAP1-activated MSTO-211H mesothelioma xenograft model, but not in the Hippo-independent HCT116 colon cancer xenograft model. Our data demonstrate that, in the context of a Hippo pathway mutated background, YAP1 activity alone is enough to maintain the growth of established tumors in vivo, thus validating the concept of inhibiting the activated YAP1-TEAD complex for the treatment of malignant pleural mesothelioma patients.

Indexed as

MesotheliomaMesothelioma, MalignantCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansPhosphoproteinsYAP-Signaling ProteinsPhosphoproteinsYAP1 protein, humanYAP-Signaling ProteinsMalignant mesotheliomaTumor maintenanceYAP1YAP-TEAD transcription signature

Identifiers

PMID35689194
PMCPMC9188206
OpenAlexW4281645037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.